Portal de Periódicos da CAPES

ASSOCIATION OF HYPERTENSION WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA

2004; Lippincott Williams & Wilkins; Volume: 172; Issue: 4 Part 1 Linguagem: Inglês

10.1097/01.ju.0000139995.85780.d8

1527-3792

Martin C. Michel, Uwe Heemann, Helmut Schumacher, LUDWIG MEHLBURGER, Μ. Goepel,

Pharmacology and Obesity Treatment

No AccessJournal of UrologyAdult Urology: Voiding Dysfunction1 Oct 2004ASSOCIATION OF HYPERTENSION WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA MARTIN C. MICHEL, UWE HEEMANN, HELMUT SCHUMACHER, LUDWIG MEHLBURGER, and MARK GOEPEL MARTIN C. MICHELMARTIN C. MICHEL Financial interest and/or other relationship with Boehringer, Yamanouchi, Sanofi-Synthelabo, Theravance and Pfizer. More articles by this author , UWE HEEMANNUWE HEEMANN More articles by this author , HELMUT SCHUMACHERHELMUT SCHUMACHER Financial interest and/or other relationship with Boehringer Ingelheim. More articles by this author , LUDWIG MEHLBURGERLUDWIG MEHLBURGER Financial interest and/or other relationship with Boehringer Ingelheim. More articles by this author , and MARK GOEPELMARK GOEPEL More articles by this author View All Author Informationhttps://doi.org/10.1097/01.ju.0000139995.85780.d8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determined whether the intensity of benign prostatic hyperplasia (BPH) symptoms and arterial hypertension are associated. Materials and Methods: Baseline data from a large sample of men seeking treatment for BPH symptoms were analyzed retrospectively. BPH symptom intensity (assessed by the International Prostatic Symptom Score [I-PSS] or urinary flow rate [Qmax]) and blood pressure were determined in 9,857 patients with BPH. Normotension was defined as a diastolic blood pressure of 90 mm Hg or less, the absence of the diagnosis hypertension and the lack of antihypertensive medication (in 4,725). Hypertension was concomitantly defined as a diastolic blood pressure of greater than 90 mm Hg (in 1,727), being diagnosed with hypertension (1,950) or the current prescription of anti-hypertensive drugs (3,360 patients). Results: When age and presence of hypertension were used as the independent explanatory variables, each year of age contributed 0.13 points and measured hypertension 1.60 points to I-PSS as the dependent response variable. Similar results were obtained with Qmax as the dependent response variable. In a logistic regression procedure using age, I-PSS and Qmax as the independent explanatory variables, each year of age and each I-PSS point significantly increased the risk of being hypertensive by 5.3% and 5.0%, respectively, while Qmax did not yield a statistically significant contribution to that risk. Conclusions: We conclude that a significant, age independent association exists between BPH symptoms and hypertension. This finding indicates a common pathophysiological factor for both disease states such as increased sympathetic activity. References 1 : The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl1995; 168: 7. Google Scholar 2 : Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol1966; 38: 18. Google Scholar 3 : Prostatic hypertrophy in greater Boston. J Chronic Dis1978; 31: 357. Google Scholar 4 : Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology1991; 38: 13. Google Scholar 5 : The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol1985; 121: 78. Google Scholar 6 : Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?. J Urol1998; 160: 784. Link, Google Scholar 7 : Epidemiology of risk factors for hypertension: implications for prevention and therapy. Drugs1999; 57: 695. Google Scholar 8 : The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Exp Physiol1999; 84: 137. Google Scholar 9 : Neurally mediated hyperactive voiding in spontaneously hypertensive rats. Brain Res1998; 790: 151. Google Scholar 10 : Plasma catecholamines and essential hypertension. An analytical review. Hypertension1983; 5: 86. Google Scholar 11 : Peripheral adrenergic receptors in hypertension. Hypertension1990; 16: 107. Google Scholar 12 : Alpha-blockers and lower urinary tract function: more than smooth muscle relaxation?. BJU Int2000; 86: 23. Google Scholar 13 : The norepinephrine tissue concentration and neuropeptide Y immunoreactivity in genitourinary organs of the spontaneously hypertensive rat. J Auton Nerv System1996; 56: 215. Google Scholar 14 : Physical activity and benign prostatic hyperplasia. Arch Intern Med1998; 158: 2349. Google Scholar 15 : Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol2003; 43: 381. Google Scholar 16 : The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med1996; 335: 533. Google Scholar 17 : Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol1998; 34: 169. Google Scholar 18 : Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology2003; 61: 119. Google Scholar 19 Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA2000; 283: 1967. Google Scholar From the Department of Pharmacology and Pharmacotherapy, University of Amsterdam, Amsterdam, the Netherlands (MCM), Department of Nephrology, Klinikum rechts der Isar, Technical University, Munich (UH), Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim (HS, LM), and Department of Urology, Klinikum Niederberg, Velbert (MG), Germany© 2004 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByLusty A, Siemens D, Tohidi M, Whitehead M, Tranmer J and Nickel J (2021) Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based StudyJournal of Urology, VOL. 205, NO. 5, (1430-1437), Online publication date: 1-May-2021.Kaplan S (2016) Re: Can Metabolic Disorders in Aging Men Contribute to Prostatic Hyperplasia Eligible for Transurethral Resection of the Prostate (TURP)?Journal of Urology, VOL. 197, NO. 1, (220-222), Online publication date: 1-Jan-2017.Griebling T (2016) Re: Relationship between Metabolic Syndrome and Lower Urinary Tract Symptoms: Hallym Aging StudyJournal of Urology, VOL. 196, NO. 4, (1217-1217), Online publication date: 1-Oct-2016.SCHNEIDER T, HEIN P, BAI J and MICHEL M (2018) A ROLE FOR MUSCARINIC RECEPTORS OR RHO-KINASE IN HYPERTENSION ASSOCIATED RAT BLADDER DYSFUNCTION?Journal of Urology, VOL. 173, NO. 6, (2178-2181), Online publication date: 1-Jun-2005. Volume 172Issue 4 Part 1October 2004Page: 1390-1393 Advertisement Copyright & Permissions© 2004 by American Urological Association, Inc.Keywordsepidemiologyhypertensionagingprostatic hyperplasiaMetricsAuthor Information MARTIN C. MICHEL Financial interest and/or other relationship with Boehringer, Yamanouchi, Sanofi-Synthelabo, Theravance and Pfizer. More articles by this author UWE HEEMANN More articles by this author HELMUT SCHUMACHER Financial interest and/or other relationship with Boehringer Ingelheim. More articles by this author LUDWIG MEHLBURGER Financial interest and/or other relationship with Boehringer Ingelheim. More articles by this author MARK GOEPEL More articles by this author Expand All Advertisement PDF DownloadLoading ...